Edition:
United States

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

6.51USD
21 Apr 2017
Change (% chg)

$-0.10 (-1.51%)
Prev Close
$6.61
Open
$6.57
Day's High
$6.66
Day's Low
$6.37
Volume
205,954
Avg. Vol
355,798
52-wk High
$9.25
52-wk Low
$2.49

Latest Key Developments (Source: Significant Developments)

BioCryst expands development of BCX7353 to explore treatment of acute HAE attacks
Wednesday, 12 Apr 2017 06:45am EDT 

BioCryst Pharmaceuticals Inc - : BioCryst expands development of BCX7353 to explore treatment of acute HAE attacks . Has received initial regulatory approvals in Europe to initiate zenith-1 exploratory clinical trial this summer .To explore if single oral doses of liquid formulation of BCX7353 could have utility in treatment of acute angioedema attacks in some patients.  Full Article

BioCryst announces Mundipharma receives approval for Mundesine in Japan
Monday, 3 Apr 2017 07:18am EDT 

Biocryst Pharmaceuticals Inc : Biocryst announces Mundipharma receives approval for Mundesine in Japan .Biocryst Pharmaceuticals Inc - Mundipharma obtained regulatory approval of Mundesine by Ministry of Health, Labor and Welfare in Japan.  Full Article

Biocryst Pharmaceuticals says public offering of 5.29 mln common shares priced at $8.50 per share
Thursday, 9 Mar 2017 08:26pm EST 

Biocryst Pharmaceuticals Inc : Biocryst pharmaceuticals prices public offering of common stock .Says public offering of 5.29 million common shares priced at $8.50 per share.  Full Article

Biocryst Pharma commences public offering of common stock
Wednesday, 8 Mar 2017 04:01pm EST 

Biocryst Pharmaceuticals Inc : Biocryst Pharmaceuticals commences public offering of common stock . Says offering to sell $45.0 million of its common stock in an underwritten public offering .Says all of shares to be sold in offering are being sold by Biocryst.  Full Article

D. E. Shaw & Co reports 5 pct passive stake in Biocryst Pharmaceuticals as of Feb 23, 2017
Monday, 6 Mar 2017 04:22pm EST 

D. E. Shaw & Co, LP:D. E. Shaw & Co, L.P. reports 5 percent passive stake in Biocryst Pharmaceuticals Inc as of Feb 23, 2017 -sec filing.  Full Article

BioCryst Pharmaceuticals Q4 loss per share $0.06
Monday, 27 Feb 2017 06:15am EST 

Biocryst Pharmaceuticals Inc : Biocryst reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.06 . Q4 revenue $9.0 million versus $4.6 million . Q4 revenue view $4.1 million -- Thomson Reuters I/B/E/S . Q4 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S . BioCryst Pharmaceuticals Inc - sees its 2017 operating expenses to be in range of $53 to $73 million . BioCryst Pharmaceuticals Inc - for three months ended december 31, 2016, total revenues increased to $9.0 million from $4.6 million in Q4 of 2015 .BioCryst Pharmaceuticals Inc - expects its 2017 net operating cash use to be in range of $30 to $50 million.  Full Article

Biocryst Q3 loss $0.16/shr
Monday, 7 Nov 2016 06:48am EST 

Biocryst Pharmaceuticals Inc : Biocryst reports third quarter 2016 financial results . Q3 loss per share $0.16 . Q3 revenue $7.8 million versus $11 million . Q3 revenue view $5.8 million -- Thomson Reuters I/B/E/S . Q3 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S . Biocryst Pharmaceuticals Inc says continues to expect its 2016 net operating cash use to be in range of $55 to $75 million . Biocryst Pharmaceuticals Inc says revised its 2016 operating expenses outlook to be in range of $68 to $80 million . Biocryst Pharmaceuticals Inc - Biocryst continues to expect its 2016 net operating cash use to be in range of $55 to $75 million .Biocryst Pharmaceuticals - 2016 operating expenses to now be in range of $68 to $80 million, a reduction from previous forecasted range of $78 to $98 million.  Full Article

D. E. Shaw & Co L.P. reports passive stake of 5.1 pct in Biocryst Pharmaceuticals as of Aug. 11
Monday, 22 Aug 2016 04:46pm EDT 

Biocryst Pharmaceuticals Inc :D. E. Shaw & Co., L.P. reports a passive stake of 5.1 percent in Biocryst Pharmaceuticals Inc as of August 11, 2016 - Sec filing.  Full Article

Baker Brosadvisors LP'S Felix Baker reports a passive stake of 14.99 pct in Biocryst Pharmaceuticals
Wednesday, 17 Aug 2016 05:04pm EDT 

Biocryst Pharmaceuticals Inc : Baker Brosadvisors LP'S Felix Baker reports a passive stake of 14.99 pct in Biocryst Pharmaceuticals Inc - SEC filing .Baker Bros' Felix Baker's stake of about 11.1 million shares in Biocryst Pharmaceuticals includes 75,000 shares of co's common stock underlying options.  Full Article

Felix Baker reports stake of 14.99 pct in BioCryst Pharmaceuticals
Tuesday, 16 Aug 2016 05:59pm EDT 

BioCryst Pharmaceuticals Inc : Felix J. Baker reports a stake of 14.99% in BioCryst Pharmaceuticals Inc as of Aug 12 - SEC filing .Felix J. Baker reported a stake of 20.5% in BioCryst Pharmaceuticals Inc as of Feb 4 - SEC filing.  Full Article

More From Around the Web